Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer

Inclusion Criteria: * 1\. Histological or cytological diagnosis of prostate cancer;； * Advanced prostate cancer patients eligible for endocrine therapy, able to receive continuous androgen deprivation therapy for at least 6 months. * Serum testosterone ≥150 ng/dL (5.2nmol/L) at screening visit; * The Eastern Cooperative Oncology Group (ECOG) score is 0 to 1. Exclusion Criteria: * Diagnosed or suspected of hormone-resistant prostate cancer; * For prostate cancer patients who have had or are undergoing endocrine therapy * Patients who have previously undergone pituitectomy or adrenalectomy or have pituitary disease or adrenal dysfunction; * Those who have had any prostate surgery within 4 weeks prior to initial dosing or prostate surgery or other major surgical treatment during the planned trial period (except urinary tract obstruction relief); * The imaging results of screening visits clearly showed the presence of brain metastases;